Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Juvisé to market, develop Ponvory outside North America

The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The global rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine.

Neurostimulator to repair myelin in RRMS named breakthrough device

The U.S. Food and Drug Administration has designated SetPoint Medical’s neurostimulator a breakthrough device for the treatment of relapsing-remitting multiple sclerosis (RRMS). This designation is intended to accelerate the development of devices intending to more effectively treat or diagnose life-threatening or chronically debilitating diseases than standard approaches.

Tysabri biosimilar Tyruko now available in Germany for RRMS

Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS). As a biosimilar, Tyruko has the same safety and efficacy profile, mechanism of action, and pharmacological properties as Tysabri. Biosimilars are typically sold at lower prices than their reference medication,…

Vidofludimus calcium reduced NfL levels in progressive MS patients

Vidofludimus calcium (IMU-838), an investigational oral therapy being developed by Immunic Therapeutics for all types of multiple sclerosis (MS), has demonstrated neuroprotective effects in people with progressive forms of the disease, interim clinical trial data show. The experimental therapy was associated with reductions in neurofilament light chain (NfL)…

Fatigue not eased with DMTs in people with MS: Study

Using disease-modifying therapies (DMTs) doesn’t reduce fatigue levels in people with multiple sclerosis (MS), a study in Norway suggests. Anxiety and depression were both associated with fatigue, suggesting “there are other underlying causes of fatigue than focal inflammation, on which DMTs have an effect,” the study’s researchers wrote…